Celldex Therapeutics (CLDX) Reports In-Line Q2 EPS

Celldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.32), in-line with the analyst estimate of ($0.32). Revenue for the quarter came in at $592 thousand versus the consensus estimate of $340 thousand.

For earnings history and earnings-related data on Celldex Therapeutics (CLDX) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Goldman starts Talen at buy, sees PJM power tightness boosting earnings
• Pfizer reaffirms 2026 guidance after CFO transition news